Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,075 | 3 | 89.8% |
| Travel and Lodging | $866.44 | 3 | 9.6% |
| Food and Beverage | $34.85 | 2 | 0.4% |
| Education | $13.93 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Myriad Genetic Laboratories, Inc. | $8,941 | 6 | $0 (2024) |
| Kite Pharma, Inc. | $22.98 | 1 | $0 (2022) |
| Acrotech Biopharma LLC | $13.93 | 1 | $0 (2021) |
| Clovis Oncology, Inc. | $11.87 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,941 | 6 | Myriad Genetic Laboratories, Inc. ($8,941) |
| 2022 | $22.98 | 1 | Kite Pharma, Inc. ($22.98) |
| 2021 | $13.93 | 1 | Acrotech Biopharma LLC ($13.93) |
| 2017 | $11.87 | 1 | Clovis Oncology, Inc. ($11.87) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | Myriad Genetic Laboratories, Inc. | PRECISETUMOR (Device) | Consulting Fee | In-kind items and services | $1,487.50 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Myriad Genetic Laboratories, Inc. | PRECISETUMOR (Device) | Travel and Lodging | In-kind items and services | $51.00 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | Myriad Genetic Laboratories, Inc. | PRECISETUMOR (Device) | Consulting Fee | In-kind items and services | $5,100.00 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | Myriad Genetic Laboratories, Inc. | PRECISETUMOR (Device) | Consulting Fee | In-kind items and services | $1,487.50 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | Myriad Genetic Laboratories, Inc. | PRECISETUMOR (Device) | Travel and Lodging | In-kind items and services | $96.48 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2024 | Myriad Genetic Laboratories, Inc. | PRECISETUMOR (Device) | Travel and Lodging | In-kind items and services | $718.96 | General |
| Category: ONCOLOGY | ||||||
| 02/25/2022 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $22.98 | General |
| 08/04/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $13.93 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2017 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $11.87 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 375 | 2,640 | $535,157 | $73,762 |
| 2022 | 16 | 461 | 7,195 | $804,984 | $99,974 |
| 2021 | 8 | 311 | 1,277 | $342,049 | $58,182 |
| 2020 | 14 | 436 | 2,703 | $463,461 | $68,555 |
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 66 | 252 | $85,837 | $23,812 | 27.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 32 | 229 | $243,656 | $22,262 | 9.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 132 | 219 | $51,764 | $12,627 | 24.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 29 | $15,080 | $3,836 | 25.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 23 | 277 | $54,292 | $3,225 | 5.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $10,155 | $2,509 | 24.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 51 | $27,948 | $2,452 | 8.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 24 | $10,176 | $1,108 | 10.9% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 14 | 122 | $13,908 | $759.21 | 5.5% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 14 | 22 | $7,062 | $626.78 | 8.9% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 15 | 580 | $14,500 | $465.12 | 3.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 17 | 820 | $779.00 | $78.85 | 10.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 74 | 298 | $96,254 | $27,701 | 28.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 41 | 242 | $251,196 | $24,912 | 9.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 135 | 254 | $57,658 | $15,634 | 27.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 11 | 93 | $215,388 | $12,760 | 5.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $19,770 | $4,818 | 24.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 30 | 237 | $45,267 | $2,873 | 6.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 15 | 53 | $28,355 | $2,716 | 9.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 18 | $9,108 | $1,982 | 21.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 11 | 31 | $12,834 | $1,565 | 12.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 12 | 58 | $15,370 | $1,260 | 8.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 12 | 95 | $8,550 | $1,031 | 12.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 13 | 39 | $10,569 | $906.54 | 8.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 12 | 37 | $8,325 | $868.64 | 10.4% |
About Dr. Michael Jones, MD
Dr. Michael Jones, MD is a Medical Oncology healthcare provider based in Fond Du Lac, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1164403226.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Jones, MD has received a total of $8,990 in payments from pharmaceutical and medical device companies, with $8,941 received in 2024. These payments were reported across 9 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($8,075).
As a Medicare-enrolled provider, Jones has provided services to 1,583 Medicare beneficiaries, totaling 13,815 services with total Medicare billing of $300,472. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Practice Information
- Specialty Medical Oncology
- Location Fond Du Lac, WI
- Active Since 11/07/2005
- Last Updated 11/12/2020
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1164403226
Products in Payments
- PRECISETUMOR (Device) $8,941
- BELEODAQ (Drug) $13.93
- Rubraca (Drug) $11.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.